Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
← catalyst calendarNCT06486441 · readout ≤ 1,046 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
640estimated
Sites
189
Countries
Australia, Brazil, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-28 | actual | When the study began enrolling |
| Primary completion | Jun 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Cancer
Interventions
- Drug: Sacituzumab govitecan-hziy — also filed as Trodelvy™, GS-0132
- Drug: Doxorubicin — also filed as Adriamycin
- Drug: Paclitaxel — also filed as Taxol
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR)
measured Up to approximately 27 months
Overall Survival (OS)
measured Up to approximately 47 months
Publications
- PMID 41073155 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed